All Stories

  1. Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, August 2019, Taylor & Francis

    Laszlo Gulacsi, Prof Márta Péntek

  2. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases

    Article • Current Pharmaceutical Design, February 2018, Bentham Science Publishers

    Laszlo Gulacsi, Zsombor Zrubka, Prof Márta Péntek

  3. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe

    Article • United European Gastroenterology Journal, May 2017, SAGE Publications

    Laszlo Gulacsi

  4. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, April 2017, Taylor & Francis

    Laszlo Gulacsi, Prof Márta Péntek

  5. Biological drug survival in RA

    Article • ClinicoEconomics and Outcomes Research, February 2017, Dove Medical Press

    Prof Márta Péntek, Laszlo Gulacsi